MetaStat, Inc. Share Price

MTST

US59140A2033

Biotechnology & Medical Research

Market Closed - OTC Markets 14:38:32 03/06/2025 BST			5-day change	1st Jan Change
0.000100 ^USD	-96.67%		-99.82%	-83.33%

21/06/18	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
03/08/17	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
MTST Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	529K 461K 436K 396K 740K 50.74M 744K 5.19M 2.01M 25.77M 1.99M 1.94M 82.52M	P/E 2017	-0.72x	P/E 2018	-2.02x
Enterprise Value	1.21M 1.06M 999K 907K 1.7M 116M 1.71M 11.89M 4.6M 59.04M 4.55M 4.45M 189M	EV / Sales 2017	-	EV / Sales 2018	329,023,519x
Free-Float	98.43%	Yield 2017 *	-	Yield 2018	-

21/06/18	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
03/08/17	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI
02/08/17	MetaStat, Inc. announced that it has received $2.57 million in funding	CI
22/06/17	MetaStat, Inc. announced that it expects to receive $7 million in funding	CI
19/06/17	MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	CI
31/05/17	MetaStat, Inc. Appoints Paul Billings to its Board of Directors, Effective as of May 24, 2017	CI
08/05/17	MetaStat, Inc. Announces Management Changes	CI
08/05/17	MetaStat, Inc. Announces Board Changes	CI
28/04/17	MetaStat, Inc. Announces Resignation of Martin J. Driscoll from the Board of Directors	CI
06/04/17	MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	CI
19/12/16	MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	CI
13/12/16	MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	CI
20/10/16	MetaStat, Inc. announced that it has received $2.61 million in funding	CI

1 day	-96.67%
1 week	-99.82%
Current month	-90.00%
1 month	-90.00%
3 months	-90.00%
6 months	-83.33%
Current year	-83.33%

1 month	0		0.05
Current year	0		0.05
1 year	0		0.05
3 years	0		0.08
5 years	0		0.08
10 years	0		3.45

Director	Title	Age	Since
Douglas A. Hamilton BRD	Director/Board Member	59	03/05/2017
Paul Billings BRD	Director/Board Member	73	23/05/2017

MetaStat, Inc. Share Price

Stocks

MTST

US59140A2033

Biotechnology & Medical Research

Valuation: MetaStat, Inc.

Latest news: MetaStat, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: MetaStat, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
METASTAT, INC.	-96.67%	-99.82%	-50.00%	-.--%	320K
LONZA GROUP AG	+1.23%	+1.30%	-0.69%	+9.57%	45.91B
IQVIA HOLDINGS INC.	+0.23%	+4.85%	+44.23%	+27.27%	44.25B
REVOLUTION MEDICINES, INC.	+0.52%	-5.17%	+340.58%	+520.09%	41.99B
BEONE MEDICINES AG	+1.55%	+0.70%	+8.03%	+76.45%	39.58B
CELLTRION, INC.	+1.75%	-1.53%	+12.22%	+41.11%	31.08B
MEDPACE HOLDINGS, INC.	-0.20%	+4.93%	+25.35%	+119.72%	17.21B
ASCENDIS PHARMA A/S	-3.49%	-8.35%	-	-	16.27B
EUROFINS SCIENTIFIC SE	+2.92%	+8.37%	+22.73%	+38.87%	14.96B
ICON PUBLIC LIMITED COMPANY	-2.45%	+6.38%	-1.99%	-35.16%	13.42B
Average	-9.46%	+1.38%	+44.50%	+88.66%	26.47B
Weighted average by Cap.	+0.58%	+0.68%	+71.15%	+120.61%

	2017	2018
Net sales	-	0.02 0.02 0.02 0.02 0.03 2.23 0.03 0.23 0.09 1.14 0.09 0.09 3.63
Net income	-2.94M -2.56M -2.43M -2.2M -4.12M -282M -4.14M -28.86M -11.16M -143M -11.05M -10.8M -459M	-3.18M -2.77M -2.62M -2.38M -4.45M -305M -4.47M -31.21M -12.07M -155M -11.95M -11.68M -496M
Net Debt	206K 180K 170K 155K 289K 19.8M 290K 2.03M 783K 10.05M 775K 758K 32.19M	683K 595K 563K 511K 956K 65.52M 961K 6.7M 2.59M 33.27M 2.57M 2.51M 107M